Our results also indicate high to moderate impact, with p<0.05 (BLM, DICER1, EFTUD2, EGFR, HELLS, MKI67, PLK1, POLE2) to moderate impact, with p>0.05 (DDX55, DTL, EXO1, FANCI, FANCM, HNRNPM, HSPA4, PRC1, PTEN, UBE2I, UBOX4) on survival outcomes of these 20 hub genes in CRC patients. This evidence concerns the gene POLE2 and colorectal carcinoma.